Improving glycemic control and cardiometabolic risk through integrated treatment plans

Journal of the American Osteopathic Association

Volumn 110, Issue 7 SUPPL. 7, 2010, Pages

  Lavernia, Frank ^a  

^a North Broward Diabetes Center in Pompano Beach   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; METFORMIN;

DIABETES MELLITUS; DISEASE COURSE; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; RISK REDUCTION;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; METFORMIN; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77957230426     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979;241(19):2035-2038.
2. Non-modifiable risk factors. American Diabetes Association Web site. http://professional.diabetes.org/ResourcesForProfessionals.aspx?typ=17&cid=60390. Accessed June 28, 2010.
3. Modifiable risk factors. American Diabetes Association Web site. http://professional.diabetes.org/ResourcesForProfessionals.aspx?cid=60382. Accessed June 28, 2010.
4. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129-1134. http://care.diabetesjournals.org/content/25/7/1129.long. Accessed June 28, 2010.
5. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359(9324):2140-2144.
6. American Diabetes Association. Standards of medical care in diabetes-2010 [published correction appears in Diabetes Care. 2010;33(3):692]. Diabetes Care. 2010:33(suppl 1):S11-S61.
7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. http://content.nejm.org/cgi/content/full/346/6/393. Accessed June 28, 2010.
8. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
9. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544.
10. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic ß-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796-2803. http://diabetes.diabetesjournals.org/content/51/9/2796.long. Accessed June 28, 2010.
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072-2077.
12. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial [published correction appears in Lancet. 2006;368(9549):1770]. Lancet. 2006;368(9541):1096-1105.
13. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) [published online ahead of print January 4, 2006]. Diabetologia. 2006;49(2):289-297.
14. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes [published online ahead of print June 5, 2009]. Diabetes Care. 2009;32(7):1327-1334. http://care.diabetesjournals.org/content/32/7/1327.long. Accessed June 29, 2010.
15. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27454/?tool=pubmed. Accessed June 29, 2010.
16. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in Endocr Pract. 2008; 14(6):802-803]. Endocr Pract. 2007;13(suppl 1):1-68. http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf. Accessed June 29, 2010.
17. National Diabetes Information Clearinghouse. Insulin Resistance and Prediabetes. Bethesda, MD: National Institutes of Health; October 2008. NIH Publication No. 09-4893 http://diabetes.niddk.nih.gov/dm/pubs/insulinresistance/insulinresistance.pdf. Accessed June 29, 2010.
18. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54(1):1-7. http://diabetes.diabetesjournals.org/content/54/1/1.long. Accessed June 29, 2010.
19. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26(5):881-885. http://care.diabetesjournals.org/content/26/3/881.long. Accessed June 29, 2010.
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes [published online ahead of print September 10, 2008]. N Engl J Med. 2008;359(15):1577-1589.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853.
22. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al; VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published online ahead of print December 17, 2008]. N Engl J Med. 2009; 360(2):129-139.
23. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes [published online ahead of print June 6, 2008]. N Engl J Med. 2008;358(24):2545-2559.
24. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [published online ahead of print June 6, 2008]. N Engl J Med. 2008;358(24):2560-2572.
25. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-2581.
26. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus [published online ahead of print March 14, 2010]. N Engl J Med. 2010; 362(17):1575-1585.
27. Jawa AA, Fonseca VA. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiol Clin. 2005;23(2):119-138.
28. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, et al. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol. 2008;158(1):35-46. http://eje-online.org/cgi/content/full/158/1/35. Accessed June 29, 2010.
29. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association [published online ahead of print December 27, 2006]. Circulation. 2007;115(1):114-126. http://circ.ahajournals.org/cgi/content/full/115/1/114. Accessed June 29, 2010.
30. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in N Engl J Med. 2010;362(18):1748]. N Engl J Med. 2010;362(17):1563-1574.
31. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2004;27(suppl 1):s72-s73. http://care.diabetesjournals.org/content/27/suppl_1/s72.full. Accessed July 8, 2010.
32. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab. 2007;9(1):96-102.
33. Westphal S, Palumbo PJ. Weight gain and management concerns in patients on insulin therapy. Insulin. 2007;2:31.
34. Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(12):4037-4043. http://jcem.endojournals.org/cgi/content/full/82/12/4037. Accessed June 29, 2010.